HR586-119

What This Bill Does

The Vietnam Veterans Liver Fluke Cancer Study Act requires the Secretary of Veterans Affairs, in consultation with the Director of the Centers for Disease Control and Prevention, to begin an epidemiological study within 120 days on the prevalence of cholangiocarcinoma, or bile duct cancer, in veterans who served in the Vietnam theater of operations during the Vietnam era. The study must use the Veterans Affairs Central Cancer Registry and the National Program of Cancer Registries. It must identify cholangiocarcinoma incidence rates among covered Vietnam-era veterans and U.S. residents from the beginning of the Vietnam era through enactment, and it must break down affected individuals by age, gender, race, ethnicity, and geographic location at diagnosis.

VA must submit a congressional report within one year after completing the study with results and recommendations for administrative or legislative action. The Secretary must also periodically submit follow-up reports and track the disease's prevalence in covered Vietnam-era veterans using the VA Central Cancer Registry. A separate provision extends a limitation date for certain veterans pension payments from November 30, 2031 to December 31, 2031.

Who Benefits and How

Vietnam-theater veterans, veterans diagnosed with cholangiocarcinoma, families of veterans with bile duct cancer, VA cancer researchers, CDC cancer-registry experts, veterans service organizations, House Veterans' Affairs Committee staff, Senate Veterans' Affairs Committee staff, and veterans receiving affected pension payments benefit because the bill creates service-era-specific cancer data, demographic comparisons, follow-up reporting, and recommendations that can inform future benefits, screening, and health-policy decisions.

Who Bears the Burden and How

The Secretary of Veterans Affairs, VA epidemiology staff, VA Central Cancer Registry staff, CDC National Program of Cancer Registries staff, VA pension administrators, and congressional oversight staff bear compliance burdens because they must launch the study within 120 days, compare cancer data across veteran and U.S. populations, prepare recommendations, track ongoing prevalence, and produce initial and follow-up reports.

Key Provisions

• Requires VA to begin a cholangiocarcinoma epidemiological study for Vietnam-theater veterans within 120 days.
• Requires consultation with CDC and use of VA Central Cancer Registry and National Program of Cancer Registries data.
• Requires incidence comparisons between covered Vietnam-era veterans and U.S. residents.
• Requires demographic analysis by age, gender, race, ethnicity, and geographic location at diagnosis.
• Requires a congressional report with findings and administrative or legislative recommendations within one year after study completion.
• Requires periodic follow-up reports and ongoing VA tracking of cholangiocarcinoma prevalence in covered veterans.
• Extends a veterans pension-payment limitation date from November 30, 2031 to December 31, 2031.